It’s a random thought ref our HNWI (s). Why did the bod feel the need to refer to them as HNWI, why not just say we’ve received an investment from a private individual. After all if an individual throws £1m+ at a AIM listed company that was sitting sub a penny shortly before, isn’t it obvious they are of high net wealth?
I think it indicates that the person (s) is someone very well known (Possibly BG as T2 has suggested). And the BoD, although clearly instructed not to reveal the identity were using the term as a statement of respect for the individuals status.
Just my thoughts, probably total BS but there you go :-)
With regards to why they opted to delay the publication. I believe they have something that's related to covid, considering the interest in that field they were keen to ensure competitors didn't get a head start on their potential discovery. After all just because a patent application is filed it does not mean it will be granted, and the process can take many years. I believe they wanted to get the patent filed and therefore get the priority date fixed and then work on the finer details. Just my thoughts.
I agree with Potnak with regards to JR comment "the world will find out" . He was referring to the fact that they had opted for delayed publication of the patent, and in 18 months time when its published its then in the public domain, for everyone to see. I don't think he meant anymore than that.
That's correct T2, any income (sale or license) that relates to a UK patent benefits from a flat 10% CT. I've been using a patent lawyer for the past couple of years and just discovered he was at AZ for 17 years, spending the last 8 as senior patent director.
Potnak, I will politely disagree. If you read the Covid update RNS:
“Subject to successful completion of the ongoing preclinical toxicology studies, requisite approvals and financing, the Company aims to commence Phase 1 clinical trials for SDC-1801 in early 2022. The timing and design of the clinical trials for Covid-19 applications will be determined following consultations with experts in the field.”
The final sentence (in my opinion) clearly states that they intend to run to separate trials. Otherwise why state:
“The timing and design of the clinical trials for Covid-19 applications will be determined following consultations with experts in the field.
If it’s the same clinical trial why repeat the statement?
"While we continue to build this wall of defence from Covid-19, it's also vital we do everything we can to protect the country for the future too - whether that's from the virus as we know it or new variants," he said.“
My take is that Gov Covid trial funding is secured and it’s now a matter of clarification with regards to trial design.
If you reread the RNS from Mon, 9th Aug 2021 13:26
“Clinical trial plans, including priority autoimmune indications and potential Covid-19 application, will also be developed in parallel, subject to additional funding being raised.”
Note subject to funding.
Then the latest trading update RNS:
“The Company aims to commence Phase 1 clinical trials for SDC-1801 in early 2022, subject to successful completion of the ongoing preclinical toxicology studies, gaining the requisite approval and financing. ( new sentence) The timing and design of the clinical trials for Covid-19 applications will be determined following consultations with experts in the field.”
No mention of subject to funding ref Covid. Also of interest is the earlier RNS states “POTENTIAL” Covid applications, whereas the latter does not use the word potential, simply Covid-19 applications.
Potnak; I don’t think the BOD are in a position say anymore than they have ref Covid applications.
“The timing and design of the clinical trials for Covid-19 applications will be determined following consultations with experts in the field.”
That suggests that they are waiting on others, most probably those overseeing the various trials.
Personally I still think they are progressing as planned with a U.K. gov trial platform. The lead prof of the U.K. Agile trials was also a contributor to the GenOMICC (Genetics Of Mortality In Critical Care) genome-wide association study in 2,244 critically ill patients with COVID-19 from 208 UK intensive care units, the subsequent Nature article that highlighted tyk2 was the springboard.
The science hasn’t changed and I’m yet to see a valid argument or reason why they would suddenly drop any promisingly treatment for c19.
RE: Looks like very good news could be on its way20 Aug 2021 14:54
Bearded Dragon. Quick explanation without going into the technical scientific aspects. When the cadre of clowns show up it’s generally because they are trying to drive the price down further. This has subsequently been followed by good news and a rise in SP. if your a chart/equation person put the following into your software: womble, clown, chickens male counterpart. The equation should produce the following user names: classic123, senator bum time and tiny Trimme.
This review focuses on the growing evidence from genomic and proteomic screens, as well as molecular studies that link TYK2 to cancer prevalence, prognosis, and metastasis. In addition, pharmacological inhibition of TYK2 is currently used clinically for autoimmune diseases, and now provides promising treatment modalities as effective therapeutic agents against multiple types of cancer.